Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989319 | 0.87 | GAA (0.73) | ALDH1A1HPGDRAB9AMAPTNPC1 | |
| SCHEMBL9517500 | 0.86 | ALDH1A1 (0.68) | ALDH1A1HPGDRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18231632 | 0.85 | NPC1 (0.71) | ALDH1A1HPGDRAB9AMAPTNPC1 | |
| SCHEMBL14465834 | 0.85 | ALDH1A1 (0.62) | ALDH1A1HPGDRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1395934 | 0.84 | ALDH1A1 (0.71) | ALDH1A1HPGDRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL925339 | 0.84 | MAPT (0.64) | ALDH1A1HPGDRAB9AMAPTNPC1 | |
| SCHEMBL31570085 | 0.84 | MAPT (0.64) | ALDH1A1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL14584390 | 0.83 | RAB9A (0.72) | ALDH1A1HPGDRAB9AMAPTSMN1; SMN2 | |
| SCHEMBL17475956 | 0.82 | MAPT (0.62) | ALDH1A1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL7687241 | 0.82 | MAPT (0.62) | ALDH1A1HPGDRAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097972-A2 | COMPOUNDS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-113754587-B | Phenylpyrazole compound and application thereof | 沈阳药科大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-113754587-A | Phenylpyrazole compound and application thereof | 沈阳药科大学 | 2021-12-07 | — | — | CN | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3261678-B1 | ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES | HELIX BIOPHARMA CORP (CA) | 2020-11-11 | — | — | EP | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| EP-3666289-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-1249233-B9 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| EP-1249233-B1 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070036714-A1 | Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy | UNIVERSITE DE RENNES 1 (FR) | 2007-02-15 | — | — | US | disclosed |
| US-20070036714-A1 | Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy | UNIVERSITE DE RENNES 1 (FR) | 2007-02-15 | — | — | US | disclosed |
| US-4521422-A | ANTICONVULSANT, ANTIEPILEPTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS | AMERICAN CYANAMID COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0129847-A2 | Aryl and heteroaryl[7-(aryl and heteroaryl)-pyrazolo-[1,5-a]-pyrimidin-3-yl]methanones | AMERICAN CYANAMID COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | ALDH1A1 1130/4885HPGD 4477/4885RAB9A 1610/4885 |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ALDH1A1 743/4885HPGD 1217/4885RAB9A 4030/4885 |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | ALDH1A1 2008/4885HPGD 901/4885RAB9A 1944/4885 |
| US-20070036714-A1 | Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy | HCCS, TFRC, ABCB7 | ALDH1A1 1529/4885HPGD 3192/4885RAB9A 3470/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | ALDH1A1 1985/4885HPGD 1503/4885RAB9A 2332/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | ALDH1A1 4604/4885HPGD 4641/4885RAB9A 3339/4885 |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ALDH1A1 743/4885HPGD 1217/4885RAB9A 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.